A Retrospective Clinicopathological Study of 37 Patients with Chordoma: a Danish National Series
Affiliations
Purpose. There are, in general, few published series on chordoma. It is a rare disease and further data are still needed.Patients/methods. The data of 37 patients with chordoma were retrospectively analyzed. Treatment was surgical excision in 11, radical radiotherapy in 9 and a combination of the two in 16 cases. The male to female ratio was 2.7 : 1. Median age was 59 years (range 1-89 years).Results. The most common symptoms at diagnosis were pain (98%), neurological disturbances (42%) and incontinence (33%). The tumours were located in the sacro-coccygeal region in 68%, the spheno-occipital region in 16% and the vertebrae in 16% of the patients. Median tumour.size was 7 cm (range 1-30 cm). Local recurrence occurred in 21/36 treated cases and distant metastases developed in eight patients (23%). The median time to recurrence/progression after primary treatment was 2 years (range 1-10 years). The actuarial 5-year rates of overall, progression-free and symptom-free survival were 40%, 31% and 20%, respectively. The corresponding 10-year rates were 26%, 21% and 14%, respectively. At the time of analysis, seven patients were alive, six without evidence of disease. Four of the six patients without active disease were symptom free. A univariate analysis showed that age, sex, tumour size, histopathology, surgical safety margin, treatment modality and radiation dose did not significantly affect overall, progression-free or symptom-free survival. Only turnout site had a prognostic value with turnouts in the spheno-occipital region carrying the worst prognosis.Discussion. We conclude that effective treatment against chordomas is still lacking and a prospective multi-institutional registration study may provide more information on the optimal work-up and treatment of this rare disease.
Sacral chordoma: clinical experience of a series of 11 patients over 18 years.
Lim J, Soeharno H, Tan M Eur J Orthop Surg Traumatol. 2018; 29(1):9-15.
PMID: 30066091 DOI: 10.1007/s00590-018-2284-x.
Surgical management of chordoma: A systematic review.
Denaro L, Berton A, Ciuffreda M, Loppini M, Candela V, Brandi M J Spinal Cord Med. 2018; 43(6):797-812.
PMID: 30048230 PMC: 7808319. DOI: 10.1080/10790268.2018.1483593.
Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas.
Lin E, Scognamiglio T, Zhao Y, Schwartz T, Phillips C AJNR Am J Neuroradiol. 2018; 39(8):1509-1514.
PMID: 29903925 PMC: 7410536. DOI: 10.3174/ajnr.A5714.
Management of Locally Recurrent Chordoma of the Mobile Spine and Sacrum: A Systematic Review.
Ailon T, Torabi R, Fisher C, Rhines L, Clarke M, Bettegowda C Spine (Phila Pa 1976). 2016; 41 Suppl 20:S193-S198.
PMID: 27753782 PMC: 5552168. DOI: 10.1097/BRS.0000000000001812.
Wu Z, Zhang J, Zhang L, Jia G, Tang J, Wang L Neurosurg Rev. 2010; 33(4):451-6.
PMID: 20668904 DOI: 10.1007/s10143-010-0273-6.